Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on track for end of Q1 2025.CTX-10726 (a novel PD-1 x VEGF ...
Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase II for Metastatic Biliary Tract Cancer. According to GlobalData, Phase II drugs for Metastatic ...